Press Releases & Events

Latest News.

View All
Posted by Steffi I.
June 15, 2022
June 15, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Read More
Posted by Steffi I.
June 8, 2022
June 8, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

Read More
Posted by Steffi I.
June 2, 2022
June 2, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Read More
“My life’s work revolves around leading companies to successfully develop and commercialize therapeutics that vastly improve the lives of patients suffering from debilitating diseases. Demanding excellence is paramount to success.”
Dr. Daniel Vitt

Chief Executive Officer, President and Director

“Beautiful science should be translated into a better life for patients, otherwise, it’s still beautiful, but useless.”
Dr. Hella Kohlhof

Chief Scientific Officer

“It is my passion to work with emerging companies to develop ground-breaking technologies. Dedicated, dynamic teams can achieve a lot together when they share mutual respect and empower each other to bring out their best. Or, as the old African proverb says: If you want to go fast, go alone. If you want to go far, work together.”
Dr. Andreas Muehler

Chief Medical Officer

“Having a positive impact on patients’ lives is the ultimate objective. As a team, we must seize the opportunities to maximize the potential of our programs so that we may also maximize the benefits for patients.“
Patrick Walsh

Chief Business Officer

“It is my passion to be a member of an emerging company working with a team of extremely talented people, all focused in the same direction, with the goal of bringing life changing therapies to patients.”
Glenn Whaley

Chief Financial Officer

“My focus is, not only, to review and approve documents but to collaborate with my amazing colleagues in order to make a substantial impact for patients while creating long-term value for our investors and other stakeholders.”
Inderpal Singh

General Counsel

“I am truly honored to work with such a high-powered team on the pursuit of exciting new science. We aim to bring novel and meaningful therapeutic options to doctors and their patients with devastating inflammatory and auto-immune conditions. Each of our drug candidates is potentially best-in-class and targets a product profile designed to improve patients’ lives by combining the convenience of oral delivery, with robust efficacy and patient-friendly tolerability.“
Dr. Duane Nash

Executive Chairman

Scroll

Questions?
Get in touch.

Contact Us

Immunic, Inc. (Nasdaq: IMUX) Stock Quote:

Currency in USD. Quote data delayed at least 15 minutes.

Investor Relations